di(4-oxazolyl)ketone | 170486-49-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: di(4-oxazolyl)ketone
• 英文别名: Methanone, bis(4-oxazolyl)-；bis(1,3-oxazol-4-yl)methanone
• CAS: 170486-49-4
• 化学式: C₇H₄N₂O₃
• 分子量: 164.12
• InChiKey: PALRZVLQGJKZPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  甲基三苯基溴化膦 、 di(4-oxazolyl)ketone 在 ammonium chloride 作用下， 以 四氢呋喃 为溶剂， 以0.05 g (33.3%)的产率得到1,1-di(4-oxazolyl)ethylene
  参考文献：
  名称：

  Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and

  摘要：

  替代的6,11-乙烷-6,11-二氢苯并[b]喹啉盐，含有它们的药物组合物，以及利用它们治疗神经退行性疾病或神经毒性损伤的方法，其中替代的6,11-乙烷-6,11-二氢苯并[b]喹啉盐具有以下结构式：##STR1## 其中：R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、X 和 p 如规范中所定义。

  公开号：

  US05554620A1

文献信息

• Substituted heterocyclylisoquinolinium salts and compositions and method
  申请人：Sterling Winthrop Inc.

  公开号：US05569655A1

  公开（公告）日：1996-10-29

  Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  取代杂环异喹啉盐，含有它们的药物组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof
  申请人：STERLING WINTHROP INC.

  公开号：EP0656359A1

  公开（公告）日：1995-06-07

  Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts of Formula, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  式中的取代的 6,11-乙hano-6,11-二氢苯并[b]喹嗪盐、 含有它们的药物组合物，以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof
  申请人：STERLING WINTHROP INC.

  公开号：EP0647641A1

  公开（公告）日：1995-04-12

  Substitutued heterocyclylisoquinolinium salts of Formula pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  式的取代杂环异喹啉盐 含有它们的药物组合物，以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Discovery of 6,11-Ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium Cations, a Novel Class of N-Methyl-D-aspartate Antagonists
  作者：Chakrapani Subramanyam、John P. Mallamo、John A. Dority、William G. Earley、Virendra Kumar、Lisa D. Aimone、Brian Ault、Matthew S. Miller、Daniel A. Luttinger、Diane L. DeHaven-Hudkins

  DOI：10.1021/jm00001a006

  日期：1995.1

  6,11-Ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations 8, a novel class of N-methyl-D-aspartate (NMDA) antagonists acting at the phencyclidine site, have been identified. Structure-activity relationship studies around the lead compound 8a led to the identification of 12g (WIN 67870-2), one of the most potent compounds in this series. Compound 12g has a K-i = 1.8 +/- 0.2 nM vs [H-3]TCP binding, has 700-fold selectivity for binding to the open state of the NMDA receptor-ionophore, and was devoid of MK-801- and PCP-like behavioral effects in rats. Compound 12g was neuroprotective in cultured mouse cortical neurons and exhibited antiischemic activity in a rat middle cerebral artery occlusion/reperfusion model of focal ischemia.
• US5554620A
  申请人：——

  公开号：US5554620A

  公开（公告）日：1996-09-10